| Vanessa S Petit-vaval, APRN | |
|
1150 N 35th Ave Ste 560, Hollywood, FL 33021-5431 | |
| (954) 265-1460 | |
| (954) 265-1375 |
| Full Name | Vanessa S Petit-vaval |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 1150 N 35th Ave Ste 560, Hollywood, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295240497 | NPI | - | NPPES |
| 105261300 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | ARNP9346924 (Florida) | Secondary |
| 363L00000X | Nurse Practitioner | APRN9346924 (Florida) | Primary |
| Entity Name | Minuteclinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134191836 PECOS PAC ID: 6709850241 Enrollment ID: O20070217000007 |
News Archive
As the scientific community continues researching the novel coronavirus, experts are developing new drugs and repurposing existing ones in hopes of identifying promising candidates for treating symptoms of COVID-19.
Use of medications that are linked to increased risk of falls in the elderly can be reduced through careful review of patient files in the Electronic Health Record, new Geisinger research shows.
Titanium dioxide (TiO2) nanoparticles, found in everything from cosmetics to sunscreen to paint to vitamins, caused systemic genetic damage in mice, according to a comprehensive study conducted by researchers at UCLA's Jonsson Comprehensive Cancer Center.
ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
The Mosquito and Vector Control Association of California (MVCAC) will host its 2012 Annual Conference at the Hyatt Regency San Francisco Airport in Burlingame, California. The top issues being addressed at the conference are a new Clean Water Act permit requirement that may result in mosquito control agencies being unable to provide the same level of protection from vector-borne diseases and the recent infestation of the Asian tiger mosquito in Southern California.
› Verified 7 days ago
| Entity Name | South Broward Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578932687 PECOS PAC ID: 8123927373 Enrollment ID: O20151219000173 |
News Archive
As the scientific community continues researching the novel coronavirus, experts are developing new drugs and repurposing existing ones in hopes of identifying promising candidates for treating symptoms of COVID-19.
Use of medications that are linked to increased risk of falls in the elderly can be reduced through careful review of patient files in the Electronic Health Record, new Geisinger research shows.
Titanium dioxide (TiO2) nanoparticles, found in everything from cosmetics to sunscreen to paint to vitamins, caused systemic genetic damage in mice, according to a comprehensive study conducted by researchers at UCLA's Jonsson Comprehensive Cancer Center.
ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
The Mosquito and Vector Control Association of California (MVCAC) will host its 2012 Annual Conference at the Hyatt Regency San Francisco Airport in Burlingame, California. The top issues being addressed at the conference are a new Clean Water Act permit requirement that may result in mosquito control agencies being unable to provide the same level of protection from vector-borne diseases and the recent infestation of the Asian tiger mosquito in Southern California.
› Verified 7 days ago
| Entity Name | V4 Full Circle Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861135881 PECOS PAC ID: 1759762933 Enrollment ID: O20220719002607 |
News Archive
As the scientific community continues researching the novel coronavirus, experts are developing new drugs and repurposing existing ones in hopes of identifying promising candidates for treating symptoms of COVID-19.
Use of medications that are linked to increased risk of falls in the elderly can be reduced through careful review of patient files in the Electronic Health Record, new Geisinger research shows.
Titanium dioxide (TiO2) nanoparticles, found in everything from cosmetics to sunscreen to paint to vitamins, caused systemic genetic damage in mice, according to a comprehensive study conducted by researchers at UCLA's Jonsson Comprehensive Cancer Center.
ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
The Mosquito and Vector Control Association of California (MVCAC) will host its 2012 Annual Conference at the Hyatt Regency San Francisco Airport in Burlingame, California. The top issues being addressed at the conference are a new Clean Water Act permit requirement that may result in mosquito control agencies being unable to provide the same level of protection from vector-borne diseases and the recent infestation of the Asian tiger mosquito in Southern California.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vanessa S Petit-vaval, APRN 2900 Corporate Way, Door D, Miramar, FL 33025-3925 Ph: (954) 276-5685 | Vanessa S Petit-vaval, APRN 1150 N 35th Ave Ste 560, Hollywood, FL 33021-5431 Ph: (954) 265-1460 |
News Archive
As the scientific community continues researching the novel coronavirus, experts are developing new drugs and repurposing existing ones in hopes of identifying promising candidates for treating symptoms of COVID-19.
Use of medications that are linked to increased risk of falls in the elderly can be reduced through careful review of patient files in the Electronic Health Record, new Geisinger research shows.
Titanium dioxide (TiO2) nanoparticles, found in everything from cosmetics to sunscreen to paint to vitamins, caused systemic genetic damage in mice, according to a comprehensive study conducted by researchers at UCLA's Jonsson Comprehensive Cancer Center.
ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
The Mosquito and Vector Control Association of California (MVCAC) will host its 2012 Annual Conference at the Hyatt Regency San Francisco Airport in Burlingame, California. The top issues being addressed at the conference are a new Clean Water Act permit requirement that may result in mosquito control agencies being unable to provide the same level of protection from vector-borne diseases and the recent infestation of the Asian tiger mosquito in Southern California.
› Verified 7 days ago